Tejas Savant
Stock Analyst at Morgan Stanley
(2.35)
# 2,651
Out of 5,026 analysts
233
Total ratings
43.18%
Success rate
-1.26%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Overweight | $65 → $68 | $87.78 | -22.53% | 4 | Aug 12, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $17 | $11.82 | +43.82% | 15 | Aug 12, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $100 → $105 | $95.52 | +9.92% | 9 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Equal-Weight | $15 → $12 | $14.79 | -18.84% | 20 | Aug 4, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $65 → $69 | $69.87 | -1.25% | 10 | Jul 31, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $10 → $8 | $10.06 | -20.48% | 14 | Jul 30, 2025 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.96 | +76.99% | 9 | May 28, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $10.12 | -30.83% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $16.31 | -44.82% | 12 | May 5, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $3.31 | +51.06% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $77.95 | -74.34% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $181.69 | +1.82% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $204.48 | +22.26% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $538.92 | +25.81% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $24.63 | -6.62% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $35.83 | -21.84% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $7.80 | +169.23% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.64 | +21.95% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $13.27 | +201.43% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.98 | +509.20% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.38 | +128.57% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.08 | -10.71% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $9.13 | -45.24% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.16 | +362.96% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $65.46 | +11.52% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $178.52 | +40.04% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $6.40 | +1,462.01% | 5 | May 12, 2022 |
Tempus AI
Aug 12, 2025
Maintains: Overweight
Price Target: $65 → $68
Current: $87.78
Upside: -22.53%
10x Genomics
Aug 12, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $11.82
Upside: +43.82%
Illumina
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $95.52
Upside: +9.92%
Avantor
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $14.79
Upside: -18.84%
Hologic
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $65 → $69
Current: $69.87
Upside: -1.25%
NeoGenomics
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $10.06
Upside: -20.48%
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.96
Upside: +76.99%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $10.12
Upside: -30.83%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $16.31
Upside: -44.82%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.31
Upside: +51.06%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $77.95
Upside: -74.34%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $181.69
Upside: +1.82%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $204.48
Upside: +22.26%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $538.92
Upside: +25.81%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $24.63
Upside: -6.62%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $35.83
Upside: -21.84%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $7.80
Upside: +169.23%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.64
Upside: +21.95%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $13.27
Upside: +201.43%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.98
Upside: +509.20%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.38
Upside: +128.57%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.08
Upside: -10.71%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $9.13
Upside: -45.24%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.16
Upside: +362.96%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $65.46
Upside: +11.52%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $178.52
Upside: +40.04%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $6.40
Upside: +1,462.01%